<DOC>
	<DOCNO>NCT00798161</DOCNO>
	<brief_summary>The objective randomise part study investigate efficacy safety BI 1356 plus metformin compare BI 1356 metformin alone give 24 week drug naive previously treat ( 4 week wash-out , 2 week placebo run-in ) type 2 diabetic patient insufficient glycaemic control . For open-label part study objective estimate efficacy safety BI 1356 metformin type 2 diabetic patient poor glycaemic control 24 week</brief_summary>
	<brief_title>Safety Efficacy Linagliptin ( BI 1356 ) Plus Metformin Type 2 Diabetes , Factorial Design</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes ( drug naive pretreated ) insufficient glycaemic control ( HbA1c high equal 7.5 less 11.0 % ) , poor glycaemic control ( HbA1c high equal 11.0 % ) eligible randomisation include openlabel arm Exclusion criterion : Myocardial infarction , stroke transient ischemic attack ( TIA ) , unstable acute congestive heart failure , impaired hepatic function , treatment rosiglitazone pioglitazone , GLP1 analogue , insulin , antiobesity drug , systemic steroid , renal failure impairment , gastric bypass</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>